In recent years, studies have shown that dMMR-MSI-H CRC tumors have a high tumor mutation burden and can present new antigens on major histocompatibility complex (MHC) class I molecules, which makes them more sensitive to T cell activation therapy, while the pMMR-MSI-L CRC tumor has a low tumor mutation burden, with a low immune response rate (Ledys et al., 2018). Here, HLA-C is linked to neoplasm.